O ver the last two decades, reports of major and minor neurological sequelae after central neuraxial blockade have renewed concern regarding the potential toxicity of currently available local anesthetic agents. These reports have led to modifications in clinical practice. This review summarizes some of this clinical experience and the experimental findings that form the basis of these modifications, with particular emphasis on the rational selection of a local anesthetic for short-duration outpatient spinal anesthesia. In addition, this chapter reviews the issue of local anesthetic systemic toxicity, focusing on the recent development of lipid rescue for bupivacaine cardiotoxicity, and the extension of lipid resuscitation beyond cardiotoxicity, and even beyond the treatment of local anesthetic toxicity.
ANESTHETIC NEUROTOXICITY

Cauda Equina Syndrome and Continuous Spinal Anesthesia
In 1991, reports of cases of cauda equina syndrome after continuous spinal anesthesia (CSA) created concern regarding the potential neurotoxicity of local anesthetics. 1 Most involved lidocaine administered through microcatheters, although some occurred with other anesthetics and/or macro (epidural) catheters. In all of these cases, there was evidence of a restricted sacral block that required repetitive doses of local anesthetic to achieve an adequate level of anesthesia. It was hypothesized that the combination 33 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML and PDF text of this article on the Journal's Web site (www.asa-refresher.com). of maldistribution and the high dose of anesthetic led to neurotoxic concentrations in a restricted area of the subarachnoid space. Studies performed with models of the subarachnoid space 2 and other in vitro 3, 4 and in vivo 5, 6 investigations provided support for this mechanism of injury. Most critically, administration of anesthetic in a restricted sacral pattern induced functional loss that closely paralleled clinical injury and caused histologic damage consistent with this impairment. 5, 6 Most critically, the clinician should limit the combined anesthetic dosage used to achieve surgical anesthesia to the maximum amount reasonable to administer as a single intrathecal injection.
In response to these reported injuries, spinal microcatheters were removed from the United States market. However, they remain available in some countries, whereas CSA is still practiced in the United States using epidural equipment (particularly when dural puncture accidentally occurs during attempted epidural placement). It is therefore essential that the practitioner appreciate the factors that may contribute to neurotoxicity, and how they impact clinical management of an intrathecal catheter (Table 1 ). Most critically, the clinician should limit the combined anesthetic dosage used to achieve surgical anesthesia to the maximum amount reasonable to administer as a single intrathecal injection.
Risk Associated With Repetitive Injection After Failed Spinal Anesthesia
As with CSA, inadequate sensory block with single-injection spinal anesthesia is often the result of maldistribution. Under such circumstances, there is again the potential for repeat injections to distribute in the same pattern, resulting in neurotoxic concentrations of anesthetic within a restricted area of the subarachnoid space. Review of the ASA Closed Claims database 7 and subsequent case reports 8 have confirmed these concerns.
On the basis of these considerations, there have been suggestions for management of a failed spinal that include assessment of the likelihood of technical error and adjustment of dosage for the second injection. 7 However, adherence to these recommendations entails significant delay, as one must allow sufficient time for achievement of near-maximal block before assessing sensory anesthesia. A more efficient and even safer alternative strategy is to assume that the injected anesthetic has been administered intrathecally. Accordingly, similar to the strategy used for CSA, the practitioner should simply limit the combined anesthetic dosage to the maximum amount reasonable to administer as a single intrathecal injection.
Injury Associated With Accidental Subarachnoid Injection of an ''Epidural'' Dose
There is a third circumstance under which excessive doses of anesthetic might be delivered into the subarachnoid space in routine clinical practice-accidental injection of a dose intended for epidural administration. In the 1980s, reports of deficits associated with apparent subarachnoid administration of chloroprocaine with bisulfite generated concern that injury might occur if epidural doses of this anesthetic solution are administered intrathecally. Beginning in 1992, similar cases have been reported with lidocaine, 9 expanding this concern to include an anesthetic historically considered the gold standard of safety. These cases serve to reinforce the critical importance of the test dose and fractional administration of anesthetic during performance of epidural anesthesia. In addition, should high doses of an anesthetic be administered through a misplaced catheter, repetitive withdrawal of small volumes (4 to 5 mL) of CSF and replacement with saline should be considered, regardless of the local anesthetic.
Injury After Single-injection Lidocaine Spinal Anesthesia
The aforementioned volley of clinical reports provided compelling evidence that injury can result if high doses of any anesthetic are administered intrathecally. More surprising, two subsequent reports raised suspicion that neurological deficits might occur with administration of lidocaine at doses recommended for single-injection spinal anesthesia. 10, 11 One was a case in which cauda equina syndrome followed intrathecal injection of 100 mg of lidocaine with epinephrine. 11 The second was a prospective study of regional anesthesia from France. 10 In a database that included roughly 10,000 lidocaine spinals, there were eight cases of persistent deficits after singleinjection spinal anesthesia that could not be explained on any other basis. All of these injuries occurred with relatively high doses (Z75 mg). Two of these cases were permanent and both followed injection of 100 mg, the maximum recommended clinical dose. The lack of an alternative etiology and the occurrence of injury at the high Table 1 . Continuous Spinal Anesthesia: Guidelines for Anesthetic Administration Insert the catheter just far enough to confirm and maintain placement. Use the lowest effective local anesthetic concentration. Place a limit on the dose of local anesthetic to be used. Administer a test dose and assess the extent of any sensory and motor block. If maldistribution is suspected, use maneuvers to increase the spread of local anesthetic (change the patient's position, alter the lumbosacral curvature, switch to a solution with a different baricity). If well-distributed sensory anesthesia is not achieved before the dose limit is reached, abandon the technique.
end of the dose range made toxicity the most likely explanation. 12 Accordingly, any potential benefit of using an intrathecal lidocaine dose higher than 75 mg would seem inadequate to override the risk. In addition, epinephrine seems to increase the neurotoxic potential of intrathecal lidocaine 13 and would warrant further reduction in dose, though epinephrine would be best avoided if lidocaine is used for spinal anesthesia.
Transient Neurological Symptoms After Singleinjection Lidocaine Spinal Anesthesia
In 1993, Schneider et al. 14 reported four cases in which transient pain/dysesthesia followed administration of relatively conservative doses of intrathecal lidocaine. These symptoms were initially called ''transient radicular irritation''; however, this term was later abandoned in favor of ''transient neurological symptoms'' or ''TNS,'' owing to the lack of certainty regarding their etiology. In this initial report, all four patients were in lithotomy position, which led the authors to postulate that this position put stretch on the nerve roots of the cauda equina, reducing blood flow and potentiating toxicity. 14 A follow-up study documented a 37% incidence of TNS with spinal lidocaine, but a nearzero incidence with bupivacaine. 15 Abundant data from numerous studies have subsequently confirmed these findings and established the cofactors that contribute to the occurrence of symptoms. In addition to lithotomy, positioning for knee arthroscopy and outpatient status markedly enhance risk. 16, 17 Although self-limited, the pain can be quite severe, often exceeding that induced by the surgical procedure. Importantly, TNS is not associated with sensory loss, motor weakness, or bowel or bladder dysfunction. The etiology and significance of these symptoms remain to be established; however, discrepancies between factors affecting TNS and experimental animal toxicity cast doubt that TNS and persistent neurological deficits are mediated by the same mechanism. Although these recent issues have led to its restricted use for spinal anesthesia, lidocaine remains a popular and appropriate agent for all other applications, including epidural anesthesia.
Chloroprocaine Spinal Anesthesia: Back to the Future?
The problems associated with lidocaine spinal anesthesia, particularly the high incidence of TNS, have led many, if not most, clinicians to abandon the use of this anesthetic for spinal anesthesia. The choice of an alternative anesthetic to be used for short-duration or outpatient anesthesia has been somewhat problematic. Although there are reports describing the use of low-dose bupivacaine combined with fentanyl, many practitioners report a high failure rate with this technique, and complete recovery may still be delayed. Of other available options, neither procaine 18 nor mepivacaine 19 seem to offer sufficient advantage with respect to TNS. Some data suggest that prilocaine may be an acceptable alternative; however, there is currently no formulation of this anesthetic in the United States that would be appropriate to administer in the subarachnoid space. Despite a rather blemished past, considerable attention has been focused on the possibility of using chloroprocaine to fill this anesthetic void. Introduced into clinical practice over 50 years ago, chloroprocaine never evolved as a spinal anesthetic agent, perhaps related to the development and marketing of lidocaine. In any case, reports of neurological deficits associated with possible intrathecal injection of epidural chloroprocaine in the early 1980s raised concern regarding the potential neurotoxicity of this anesthetic, which, until recently, would have subdued any enthusiasm for deliberate intrathecal administration. Although early experimental evidence suggested that clinical toxicity derived from the bisulfite used as an antioxidant in the chloroprocaine solution, 20 other data sharply conflicted, and more recent data even suggest that this antioxidant might actually be neuroprotective. 21 The dissatisfaction with spinal lidocaine encouraged Kopacz's group to reinvestigate the use of bisulfite-free chloroprocaine for spinal anesthesia. Their rigorous systematic volunteer studies documented effective spinal anesthesia with little, if any, risk of TNS. [22] [23] [24] [25] [26] Duration of effect was shorter than with an equal dose of lidocaine 23 and institutional discharge criteria were achieved more rapidly than with lidocaine, 23 procaine, 22 or low-dose bupivacaine. 26 As expected, anesthesia could be prolonged or enhanced by coadministration of fentanyl 25 or epinephrine. 24 However, an unexpected and disturbing finding was the occurrence of ''flu-like'' symptoms in the volunteers who received chloroprocaine containing epinephrine. 24 The etiology remains obscure.
Should chloroprocaine be used for spinal anesthesia, the solution administered should be bisulfite free, the dose limited to 60 mg, and the use of epinephrine avoided.
Several clinical reports have confirmed the suitability of chloroprocaine for outpatient spinal anesthesia, in terms of both its short duration and low risk of TNS, 27 though these published data are insufficient to establish the safety of chloroprocaine as a spinal anesthetic. Nonetheless, the ''off-label'' clinical experience with the drug is substantial, and use of chloroprocaine at this point would not seem imprudent. In addition, while the issue of bisulfite toxicity has not been settled, the recent experience in volunteer studies and this ''off-label'' clinical use have been restricted to preservative-free chloroprocaine. Accordingly, should chloroprocaine be used for spinal anesthesia, the solution administered should be bisulfite free. In addition, the available data and clinical experience would suggest that the dose be limited to 60 mg, 28 and the use of epinephrine be avoided. 24 
ANESTHETIC CARDIOTOXITY AND LIPID RESCUE
Historical Context
The most feared complications associated with administration of local anesthetics are the profound effects that these agents can have on cardiac conduction and function. In the distant past, it was conventional wisdom that prompt treatment of central nervous system (CNS) toxicity, particularly maintenance of ventilation and oxygenation, could always avert cardiac catastrophe. This belief was called into question by a sentinel case reported by Prentiss, 29 in which administration of etidocaine for caudal anesthesia in a healthy 31-year-old male was associated with near simultaneous convulsions and cardiac arrest. Shortly thereafter, a seminal editorial by Albright 30 incorporated Prentiss's case, along with five others, to support the concept that the long-acting lipid-soluble anesthetic agents (etidocaine and bupivacaine) could induce profound cardiac toxicity concurrent with, or even preceding CNS toxicity, and independent of hypoxia.
Although this suggestion met with considerable resistance, cases of bupivacaine-induced cardiac collapse unfortunately continued to occur. By early 1983, the Food and Drug Administration had received reports from the pharmaceutical industry of 12 cases of cardiac arrest, 10 fatal, associated with the use of bupivacaine in obstetrics, most occurring with the 0.75% solution.
In response, the package labeling was modified, and a ''Dear Doctor'' letter was disseminated notifying clinicians that 0.75% bupivacaine was no longer to be used for obstetrical anesthesia, or any concentration to be used for intravenous regional anesthesia or paracervical block. This communication also stressed the importance of an adequate test dose, and injection of anesthetic in incremental doses. In addition to putting into play these changes in clinical practice, the occurrence of these cases stimulated an enormous research effort. The resultant literature has provided ample evidence for the distinctive cardiotoxicity of these agents, which seems to relate to the nature of bupivacaine's interaction with cardiac sodium channels. 31 Simply stated, bupivacaine might be labeled a ''fast-in, slow-out'' local anesthetic as recovery from sodium channel blockade during diastole is relatively prolonged, which would create conditions favorable for unidirectional block and reentry. Other mechanisms may contribute as well, including disruption of atrioventricular nodal conduction, depression of myocardial contractility, and indirect effects mediated by the CNS. 32 This enhanced cardiotoxicity has been the driving force for development of the single enantiomer anesthetics, ropivacaine and levobupivacaine. Unfortunately, despite these pharmaceutical advancements and the aforementioned modifications in clinical practice, cardiotoxicity has re-mained a concern, and with the exception of cardiopulmonary bypass, treatment options have been largely ineffective.
Lipid Rescue: From a Serendipitous Observation to Clinical Practice
Recently, a series of clinical events, insightful observations, systematic experimentation, and astute clinical decisions have identified a practical and apparently effective therapy for bupivacaine cardiotoxicity. In addition, this therapy seems to have applications that go well beyond the initial problem of bupivacaine cardiotoxicity, finding use in the treatment of other manifestations of local anesthetic systemic toxicity and resuscitation from cardiotoxicity secondary to a wide variety of toxicological challenges.
After learning of a case of apparent cardiotoxicity from only 22 mg of bupivacaine in a patient with carnitine deficiency, Weinberg et al. 33 postulated that this metabolic derangement led to enhanced toxicity because of the accumulation of fatty acids within cardiac myoctyes. They then hypothesized that administration of lipid would potentiate cardiotoxicity on the basis of this accumulation, a condition known to be arrhythmogenic. However, experiments they conducted to test this hypothesis demonstrated protection rather than enhancement of bupivacaine's cardiotoxicity by lipid. Encouraged by this serendipitous finding, they instituted a series of deliberate systematic investigations in rats 34 and dogs 35 that clearly demonstrated a potential benefit of intravenous lipid for treating the highly resistant cardiotoxicity of bupivacaine ( Figure 1) .
The mechanism by which lipid is effective is incompletely understood; however, its predominant effect is almost certainly related to its ability to extract bupivacaine from aqueous plasma or tissue targets, thus reducing their effective concentration (''lipid sink''). Alternatively, or additively, bupivacaine has been shown to inhibit fatty acid transport at the inner mitochondrial membrane, and lipid might act by overcoming this inhibition, thus serving to restore energy to the myocardium. Finally, fatty acids have been demonstrated to increase cardiac myocyte calcium concentrations, 36 and thus lipid emulsion might exert a direct inotropic effect.
Clinical confirmation came eight years after Weinberg's initial studies. Faced with a patient who developed cardi- 35 otoxicity refractory to standard ACLS after receiving 20 mL 0.5% bupivacaine and 20 mL 1.5% mepivacaine for an interscalene block, Rosenblatt et al. 37 administered a 100 mL bolus of 20% Intralipid (see Supplemental Digital Content 1, http://links.lww.com/ASA/A73). The patient subsequently responded to defibrillation, ultimately making a complete recovery. This report of an apparent favorable response in this single patient was enough to ignite a firestorm in interest. A second independent and nearsimultaneous report by Litz provided corroboration and extended the potential utility of this treatment to cardiotoxicity induced by ropivacaine. 38 A plethora of other reports soon followed, including one by Spence 39 
Lipid Rescue Moves Beyond the Local Anesthetics
Given the mechanism of action-partition of drug into the fat emulsion, out of serum, and away from the target sites of action-one might postulate that lipid would have efficacy for any toxicological challenge, provided the drug was lipid soluble. Such has proven to be the case. Similar to the Rosenblatt et al. 37 publication, a sentinel report by Sirianni et al. 40 provided the clinical confirmation needed to open a floodgate of corroborative case reports. The patient was a 17-year-old girl who developed cardiovascular collapse after intentional ingestion of up to 7.95 g of bupropion and 4 g of lamotrigine. After standard cardiopulmonary resuscitation for 70 minutes proved unsuccessful, a 100-mL bolus of 20% lipid emulsion was administered, resulting in recovery of a sustained pulse in roughly a minute. Although the patient's hospital course was complicated (as might be anticipated based on the long resuscitation), she was discharged with near-normal neurological function. Other cases soon followed, documenting apparent efficacy after a variety of other ingestions including verapamil, 41 quetiapine/sertraline, 42 and haloperidol. 43 Interesting, but not surprising, was a case in which lipid was associated with rapid and dramatic improvement in a patient with refractory hypotension caused by glyphosate-surfactant herbicide. 44 In addition to these anecdotal clinical reports, a recent systematic review of experimental studies identified 14 publications that met their quality criteria for inclusion. Of these, 10 demonstrated a positive effect, including enhanced survival after potentially lethal doses of clomipramine, verapamil, and propranolol. 45 
Clinical Recommendations and Possible Modifications of Advanced Cardiac Life Support
The growing body of evidence is more than sufficient to warrant administration of lipid in cases of systemic anesthetic toxicity. The agent should be administered at an initial bolus of 1.5 mL/kg of a 20% solution followed by an infusion of 0.25 mL/kg/minute. Importantly, propofol should not be administered for this purpose, as the relatively enormous volume of the standard 10% solution required for lipid therapy (approximately 200 mL) would deliver massive, potentially lethal, quantities of propofol. However, small doses of propofol might be appropriate for seizure control, particularly in the case where there would be a delay in administering a benzodiazepine. On the basis of the foregoing, it should be evident that solutions of 20% lipid should be stocked and readily accessible in any area where local anesthetics are administered, and locations where overdoses from any lipophilic drug might be treated.
The growing body of evidence is more than sufficient to warrant administration of lipid in cases of systemic anesthetic toxicity.
The agent should be administered at an initial bolus of 1.5 mL/kg of a 20% solution followed by an infusion of 0.25 mL/kg/minute.
Although there is no uncertainty regarding the use of lipid for resuscitation, two issues remain somewhat controversial-the timing of administration and its place in the resuscitation algorithm.
Potential Toxicity and Timing of Administration.
When used for parenteral nutrition, possible adverse effects associated with lipid emulsions include allergic reactions, hypercoagulability, pancreatitis, and lung injury. Although the potential toxicity of lipid emulsion given as a bolus remains poorly defined, the LD50 was found to be 67 mL/kg in a rodent model, 46 well above an order of magnitude of clinical dosing. Further, the lack of apparent overt toxicity in patients treated to date is somewhat reassuring, albeit care must be used when interpreting such information given the limited number of these patients. Although it has been argued that infusing lipid at the earliest signs of systemic toxicity could result in unnecessary treatment of some patients, exposing them to such potential toxicity, it seems imprudent to wait until severe cardiovascular dysfunction is evident. On the basis of the mechanism, efficacy will be directly related to the ability to deliver lipid to the target organ, which may be compromised by waiting. Similarly, the ability of lipid to partition anesthetic might decrease in the presence of acidosis, a condition that will favor the ionized, and less soluble, form of the drug. These considerations argue for relatively early use after recognition of any clinical symptoms of toxicity.
Modifications in the Advanced Cardiac Life Support
Protocol With Respect to Systemic Anesthetic Toxicity. Intuitively, anesthetic toxicity represents a specific problem that might not be ideally addressed with generic recommendations for treatment of cardiac arrest. There is an expanding body of evidence to support this concept. In a rat model of bupivacaine-induced cardiac arrest, DiGregorio working in Weinberg's laboratory found lipid to be more effective than vasopressin either alone or with epinephrine. 47 Furthermore, administration of vasopressin was associated with hemorrhagic pulmonary edema. In a follow-up study by Hiller et al. 48 examining the dose response to epinephrine during lipid treatment, hemodynamics returned more rapidly with the addition of epinephrine; however, this positive effect was short lived at higher doses (Z10 mcg/kg), and ultimately animals receiving these doses had worse outcome (Figure 2A) . In contrast, Mayr et al., 49 using a porcine model, found vasopressin plus epinephrine to provide better short-term survival compared with lipid infusion, though hypoxia was a potential confounding variable in these studies. In another porcine model, Hicks et al. 50 failed to find a beneficial effect of lipid emulsion when added to epinephrine and vasopressin late in resuscitation (see Supplemental Digital Content 2, http://links.lww.com/ASA/A75). Finally, a recent study by Harvey et al. 51 in rabbits observed return of circulation only when lipid was combined with high-dose epinephrine (100 mcg/kg); however, as observed by Hiller et al., 48 this treatment was subsequently associated with declining hemodynamic variables ( Figure 2B) .
Given the diversity of these models, which use different species, variable doses of both bupivacaine and resuscitative drugs, inconsistent timing of administration, and different assessments of hemodynamics and definitions of success, the lack of agreement is perhaps not surprising. But what might be concluded from this conflicting literature? It is probably fair to state that lipid can be of profound benefit in treatment of systemic anesthetic toxicity and that epinephrine might serve to augment this effect, but, at higher doses, might be detrimental. Because the relevant or optimal dose of epinephrine remains undefined, it would seem prudent to supplement lipid rescue with relatively low doses as needed to assist in return of spontaneous circulation and augment hemodynamic stability. On the basis of the limited available literature, it would seem best to avoid vasopressin, at least early in the resuscitation, though administration might be Life Support, with the following modifications: If epinephrine is used, small doses (10 to 100 mcg boluses in the adult) are preferred (IIa; C) Vasopressin is not recommended (III; B) Avoid calcium channel blockers and b-adrenergic receptor blockers (III; C) If ventricular arrhythmias develop, amiodarone is preferred (IIa; B); treatment with local anesthetics (lidocaine or procainamide) is not recommended (III; C) Lipid emulsion therapy (IIa; B):
Consider administering at the first signs of LAST, after airway management Dosing: -1.5 mL/kg 20% lipid emulsion bolus -0.25 mL/kg/minute infusion, continued for at least 10 minutes after circulatory stability is attained. -If circulatory stability is not attained, consider repeat bolus and increasing infusion to 0.5 mL/kg/min -Approximately 10 ml/kg lipid emulsion for 30 minutes is recommended as the upper limit for initial dosing. Propofol is not a substitute for lipid emulsion (III; C) Failure to respond to lipid emulsion and vasopressor therapy should prompt institution of CPB (IIa; C). Because there can be considerable lag in beginning CPB, it is reasonable to notify the closest facility capable of providing it when cardiovascular compromise is first identified during an episode of LAST. considered in cases where there has been lack of response to other measures.
Clinical Resources
A recent issue of Regional Anesthesia and Pain Medicine (March-April 2010) contains a collection of articles developed by an ASRA Practice Advisory Panel. [52] [53] [54] [55] [56] [57] The summary recommendations from this group 56 are available for download without subscription at journals.lww.com/rapm. The recommendations from this publication for treatment of systemic toxicity and the level of evidence for each intervention are presented in Table 2 . Many critical questions have yet to be addressed in this rapidly developing area, and timely information on the topic, and downloadable treatment protocols, can be found at www.lipidrescue.org, a website established and maintained by Weinberg. As a final note, because controlled trials are not ethically feasible, clinicians using lipid rescue are greatly encouraged to submit their cases (both favorable and unsuccessful) to this website.
